Clinical Trial Update: A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL [Phase 2]

View source ↗

Summary

This is a Phase 2 precision medicine trial for patients with relapsed or refractory T cell acute lymphoblastic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia

Snippet

Sponsor: Philippe ROUSSELOT | Conditions: LAL | Phase 2 | Status: NOT_YET_RECRUITING